CY1121856T1 - Αντισωματα εξουδετερωσης jcv - Google Patents
Αντισωματα εξουδετερωσης jcvInfo
- Publication number
- CY1121856T1 CY1121856T1 CY20191100809T CY191100809T CY1121856T1 CY 1121856 T1 CY1121856 T1 CY 1121856T1 CY 20191100809 T CY20191100809 T CY 20191100809T CY 191100809 T CY191100809 T CY 191100809T CY 1121856 T1 CY1121856 T1 CY 1121856T1
- Authority
- CY
- Cyprus
- Prior art keywords
- jcv
- neutralizing antibodies
- antibody
- virus
- jcv neutralizing
- Prior art date
Links
- 230000003472 neutralizing effect Effects 0.000 title abstract 3
- 241000701460 JC polyomavirus Species 0.000 abstract 2
- 108090000565 Capsid Proteins Proteins 0.000 abstract 1
- 102100023321 Ceruloplasmin Human genes 0.000 abstract 1
- SQVRNKJHWKZAKO-UHFFFAOYSA-N beta-N-Acetyl-D-neuraminic acid Natural products CC(=O)NC1C(O)CC(O)(C(O)=O)OC1C(O)C(O)CO SQVRNKJHWKZAKO-UHFFFAOYSA-N 0.000 abstract 1
- SQVRNKJHWKZAKO-OQPLDHBCSA-N sialic acid Chemical compound CC(=O)N[C@@H]1[C@@H](O)C[C@@](O)(C(O)=O)OC1[C@H](O)[C@H](O)CO SQVRNKJHWKZAKO-OQPLDHBCSA-N 0.000 abstract 1
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
- C07K16/08—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from viruses
- C07K16/081—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from viruses from DNA viruses
- C07K16/084—Papovaviridae, e.g. papillomavirus, polyomavirus, SV40, BK virus, JC virus
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/20—Immunoglobulins specific features characterized by taxonomic origin
- C07K2317/24—Immunoglobulins specific features characterized by taxonomic origin containing regions, domains or residues from different species, e.g. chimeric, humanized or veneered
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
- C07K2317/56—Immunoglobulins specific features characterized by immunoglobulin fragments variable (Fv) region, i.e. VH and/or VL
- C07K2317/565—Complementarity determining region [CDR]
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
- C07K2317/56—Immunoglobulins specific features characterized by immunoglobulin fragments variable (Fv) region, i.e. VH and/or VL
- C07K2317/567—Framework region [FR]
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
- C07K2317/76—Antagonist effect on antigen, e.g. neutralization or inhibition of binding
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/90—Immunoglobulins specific features characterized by (pharmaco)kinetic aspects or by stability of the immunoglobulin
- C07K2317/92—Affinity (KD), association rate (Ka), dissociation rate (Kd) or EC50 value
-
- Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
- Y02—TECHNOLOGIES OR APPLICATIONS FOR MITIGATION OR ADAPTATION AGAINST CLIMATE CHANGE
- Y02A—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE
- Y02A50/00—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE in human health protection, e.g. against extreme weather
- Y02A50/30—Against vector-borne diseases, e.g. mosquito-borne, fly-borne, tick-borne or waterborne diseases whose impact is exacerbated by climate change
Landscapes
- Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Medicinal Chemistry (AREA)
- Biochemistry (AREA)
- Biophysics (AREA)
- Virology (AREA)
- Genetics & Genomics (AREA)
- General Health & Medical Sciences (AREA)
- Molecular Biology (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Immunology (AREA)
- Peptides Or Proteins (AREA)
- Micro-Organisms Or Cultivation Processes Thereof (AREA)
- Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
Abstract
Σε μία μορφή η γνωστοποίηση παρέχει αντισώματα εξουδετέρωσης έναντι JCV και μεθόδους για την αγωγή της PML. Σε μερικές υλοποιήσεις, μορφές της εφεύρεσης αφορούν ένα απομονωμένο μονοκλωνικό αντίσωμα εξουδετέρωσης JC ιού έναντι πρωτεΐνης καψιδίου JCV VPI (JCV-VP1). Σε μερικές υλοποιήσεις, το αντίσωμα καταστέλλει τη μολυσματικότητα του ιού JC. Σε μερικές υλοποιήσεις, το αντίσωμα δεσμεύει την θήκη δέσμευσης σιαλικού οξέος της JCV-VP1.
Applications Claiming Priority (2)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
US201261613214P | 2012-03-20 | 2012-03-20 | |
PCT/US2013/031842 WO2013142299A1 (en) | 2012-03-20 | 2013-03-15 | Jcv neutralizing antibodies |
Publications (1)
Publication Number | Publication Date |
---|---|
CY1121856T1 true CY1121856T1 (el) | 2020-07-31 |
Family
ID=49223243
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
CY20191100809T CY1121856T1 (el) | 2012-03-20 | 2019-07-30 | Αντισωματα εξουδετερωσης jcv |
Country Status (15)
Country | Link |
---|---|
US (1) | US9567392B2 (el) |
EP (2) | EP3575311A1 (el) |
CA (1) | CA2867902C (el) |
CY (1) | CY1121856T1 (el) |
DK (1) | DK2828284T3 (el) |
ES (1) | ES2731757T3 (el) |
HR (1) | HRP20190937T1 (el) |
HU (1) | HUE044838T2 (el) |
LT (1) | LT2828284T (el) |
PL (1) | PL2828284T3 (el) |
PT (1) | PT2828284T (el) |
RS (1) | RS58910B1 (el) |
SI (1) | SI2828284T1 (el) |
TR (1) | TR201909801T4 (el) |
WO (1) | WO2013142299A1 (el) |
Families Citing this family (6)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
RS58910B1 (sr) | 2012-03-20 | 2019-08-30 | Biogen Ma Inc | Antitela koja neutrališu virus jcv |
ES2706173T3 (es) | 2012-03-20 | 2019-03-27 | Biogen Ma Inc | Anticuerpos de neutralización de JCV |
ITTO20120570A1 (it) * | 2012-06-27 | 2013-12-28 | Pomona Ricerca Srl | Anticorpo monoclonale diretto contro il virus jc |
US9862760B2 (en) | 2015-09-16 | 2018-01-09 | Novartis Ag | Polyomavirus neutralizing antibodies |
WO2019106578A2 (en) | 2017-12-01 | 2019-06-06 | Novartis Ag | Polyomavirus neutralizing antibodies |
EP3986930A4 (en) * | 2019-06-19 | 2023-04-12 | Icahn School of Medicine at Mount Sinai | MONOCLONAL ANTIBODIES TO JC VIRUS |
Family Cites Families (36)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
NL154598B (nl) | 1970-11-10 | 1977-09-15 | Organon Nv | Werkwijze voor het aantonen en bepalen van laagmoleculire verbindingen en van eiwitten die deze verbindingen specifiek kunnen binden, alsmede testverpakking. |
US3817837A (en) | 1971-05-14 | 1974-06-18 | Syva Corp | Enzyme amplification assay |
US3939350A (en) | 1974-04-29 | 1976-02-17 | Board Of Trustees Of The Leland Stanford Junior University | Fluorescent immunoassay employing total reflection for activation |
US3996345A (en) | 1974-08-12 | 1976-12-07 | Syva Company | Fluorescence quenching with immunological pairs in immunoassays |
US4275149A (en) | 1978-11-24 | 1981-06-23 | Syva Company | Macromolecular environment control in specific receptor assays |
US4277437A (en) | 1978-04-05 | 1981-07-07 | Syva Company | Kit for carrying out chemically induced fluorescence immunoassay |
US4399216A (en) | 1980-02-25 | 1983-08-16 | The Trustees Of Columbia University | Processes for inserting DNA into eucaryotic cells and for producing proteinaceous materials |
US4634665A (en) | 1980-02-25 | 1987-01-06 | The Trustees Of Columbia University In The City Of New York | Processes for inserting DNA into eucaryotic cells and for producing proteinaceous materials |
US5179017A (en) | 1980-02-25 | 1993-01-12 | The Trustees Of Columbia University In The City Of New York | Processes for inserting DNA into eucaryotic cells and for producing proteinaceous materials |
US4366241A (en) | 1980-08-07 | 1982-12-28 | Syva Company | Concentrating zone method in heterogeneous immunoassays |
US4472509A (en) | 1982-06-07 | 1984-09-18 | Gansow Otto A | Metal chelate conjugated monoclonal antibodies |
US4938948A (en) | 1985-10-07 | 1990-07-03 | Cetus Corporation | Method for imaging breast tumors using labeled monoclonal anti-human breast cancer antibodies |
GB8607679D0 (en) | 1986-03-27 | 1986-04-30 | Winter G P | Recombinant dna product |
EP0307434B2 (en) | 1987-03-18 | 1998-07-29 | Scotgen Biopharmaceuticals, Inc. | Altered antibodies |
US5892019A (en) | 1987-07-15 | 1999-04-06 | The United States Of America, As Represented By The Department Of Health And Human Services | Production of a single-gene-encoded immunoglobulin |
US5530101A (en) | 1988-12-28 | 1996-06-25 | Protein Design Labs, Inc. | Humanized immunoglobulins |
IL162181A (en) | 1988-12-28 | 2006-04-10 | Pdl Biopharma Inc | A method of producing humanized immunoglubulin, and polynucleotides encoding the same |
ATE255131T1 (de) | 1991-06-14 | 2003-12-15 | Genentech Inc | Humanisierter heregulin antikörper |
DK0678122T3 (da) | 1993-01-12 | 2000-03-06 | Biogen Inc | Rekombinante anti-VLA4 antistofmolekyler |
JP3593343B2 (ja) | 1993-02-09 | 2004-11-24 | バイオジェン インコーポレイテッド | インシュリン依存型糖尿病の治療 |
US5827690A (en) | 1993-12-20 | 1998-10-27 | Genzyme Transgenics Corporatiion | Transgenic production of antibodies in milk |
US5840299A (en) | 1994-01-25 | 1998-11-24 | Athena Neurosciences, Inc. | Humanized antibodies against leukocyte adhesion molecule VLA-4 |
DE19541844C1 (de) | 1995-11-09 | 1997-07-24 | Gsf Forschungszentrum Umwelt | Verfahren zur Herstellung von menschlichen Antikörpern und deren Verwendung |
US8288322B2 (en) | 2000-04-17 | 2012-10-16 | Dyax Corp. | Methods of constructing libraries comprising displayed and/or expressed members of a diverse family of peptides, polypeptides or proteins and the novel libraries |
JP4949373B2 (ja) | 2005-03-10 | 2012-06-06 | モルフォテック、インク. | 抗メソテリン抗体 |
CN110776566A (zh) | 2005-12-20 | 2020-02-11 | Sbi 生物技术有限公司 | 抗ilt7抗体 |
JP2009536641A (ja) | 2006-05-31 | 2009-10-15 | ハンワ ケミカル コーポレイション | Vcam−1特異的モノクローナル抗体 |
US7910702B2 (en) | 2006-07-28 | 2011-03-22 | The Governors Of The University Of Alberta | Recombinant antibodies to sclerotinia antigens |
PL2308514T3 (pl) * | 2007-03-23 | 2013-11-29 | To Bbb Holding B V | Koniugaty do ukierunkowanego dostarczania leku poprzez barierę krew-mózg |
BRPI0814060A2 (pt) | 2007-07-06 | 2015-01-06 | Trubion Pharmaceuticals Inc | Peptídeos ligantes tendo um domínio de ligação específico disposto em c-terminal |
SI3444274T1 (sl) * | 2008-06-25 | 2021-04-30 | Novartis Ag | Stabilna in topna protitelesa, ki zavirajo tnf |
EP2394163B1 (en) | 2009-02-05 | 2020-08-19 | Biogen MA Inc. | Methods for the detection of jc polyoma virus |
WO2010129959A1 (en) | 2009-05-08 | 2010-11-11 | Government Of The U.S.A., As Represented By The Secretary, Department Of Health And Human Services | Compositions and methods for the prevention and treatment of lupus nephritis using anti-dsdna germline antibodies |
EP2316481A1 (en) * | 2009-10-30 | 2011-05-04 | Biomay Ag | Pharmaceutical composition for the treatment and prevention of a rhinovirus infection |
ES2706173T3 (es) | 2012-03-20 | 2019-03-27 | Biogen Ma Inc | Anticuerpos de neutralización de JCV |
RS58910B1 (sr) | 2012-03-20 | 2019-08-30 | Biogen Ma Inc | Antitela koja neutrališu virus jcv |
-
2013
- 2013-03-15 RS RS20190730A patent/RS58910B1/sr unknown
- 2013-03-15 CA CA2867902A patent/CA2867902C/en active Active
- 2013-03-15 WO PCT/US2013/031842 patent/WO2013142299A1/en active Application Filing
- 2013-03-15 SI SI201331459T patent/SI2828284T1/sl unknown
- 2013-03-15 PL PL13765090T patent/PL2828284T3/pl unknown
- 2013-03-15 LT LTEP13765090.9T patent/LT2828284T/lt unknown
- 2013-03-15 TR TR2019/09801T patent/TR201909801T4/tr unknown
- 2013-03-15 PT PT13765090T patent/PT2828284T/pt unknown
- 2013-03-15 US US14/386,262 patent/US9567392B2/en active Active
- 2013-03-15 ES ES13765090T patent/ES2731757T3/es active Active
- 2013-03-15 DK DK13765090.9T patent/DK2828284T3/da active
- 2013-03-15 EP EP19172368.3A patent/EP3575311A1/en not_active Withdrawn
- 2013-03-15 EP EP13765090.9A patent/EP2828284B1/en active Active
- 2013-03-15 HU HUE13765090 patent/HUE044838T2/hu unknown
-
2019
- 2019-05-21 HR HRP20190937TT patent/HRP20190937T1/hr unknown
- 2019-07-30 CY CY20191100809T patent/CY1121856T1/el unknown
Also Published As
Publication number | Publication date |
---|---|
EP2828284A1 (en) | 2015-01-28 |
TR201909801T4 (tr) | 2019-07-22 |
US20150050271A1 (en) | 2015-02-19 |
US9567392B2 (en) | 2017-02-14 |
ES2731757T3 (es) | 2019-11-18 |
CA2867902A1 (en) | 2013-09-26 |
RS58910B1 (sr) | 2019-08-30 |
HUE044838T2 (hu) | 2019-11-28 |
DK2828284T3 (da) | 2019-06-11 |
WO2013142299A1 (en) | 2013-09-26 |
CA2867902C (en) | 2023-09-26 |
EP2828284A4 (en) | 2015-07-22 |
PT2828284T (pt) | 2019-06-17 |
SI2828284T1 (sl) | 2019-10-30 |
EP2828284B1 (en) | 2019-05-08 |
EP3575311A1 (en) | 2019-12-04 |
PL2828284T3 (pl) | 2019-11-29 |
HRP20190937T1 (hr) | 2019-10-04 |
LT2828284T (lt) | 2019-08-26 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
CY1121856T1 (el) | Αντισωματα εξουδετερωσης jcv | |
EA201990243A1 (ru) | Новые антитела, которые специфически связываются с эпитопами вируса зика, и их применения | |
CY1121934T1 (el) | Αντισωματα anti-fcrn | |
CY1123068T1 (el) | Εξουδετερωτικα αnτισωματα εναντι gp120 και χρηση αυτων | |
CY1120471T1 (el) | Αντισωματα κατα του cd70 | |
EA201791961A1 (ru) | Антитела, специфичные к cd47 и pd-l1 | |
CY1119789T1 (el) | Cgrp αντισωματα | |
EA201791675A1 (ru) | Человеческие антитела к гликопротеину вируса эбола | |
PH12016501384A1 (en) | Human antibodies to pd-l1 | |
EA201891992A1 (ru) | Химерные рецепторы и способы их применения | |
EA201791754A1 (ru) | АНТИТЕЛА, СОДЕРЖАЩИЕ ЗАВИСЯЩИЙ ОТ КОНЦЕНТРАЦИИ ИОНОВ АНТИГЕНСВЯЗЫВАЮЩИЙ ДОМЕН, ВАРИАНТЫ Fc-ОБЛАСТИ, IL-8-СВЯЗЫВАЮЩИЕ АНТИТЕЛА И ИХ ПРИМЕНЕНИЯ | |
WO2016196975A8 (en) | Neutralizing antibodies to hiv-1 env and their use | |
EA201790755A1 (ru) | Модуляция стимулирующих и нестимулирующих миелоидных клеток | |
EA201890874A1 (ru) | Антитела, которые эффективно нейтрализуют вирус гепатита в, и их применение | |
PE20180480A1 (es) | Anticuerpos de factor xi y metodos de uso | |
WO2017079479A8 (en) | Neutralizing antibodies to hiv-1 gp41 and their use | |
EA201491686A1 (ru) | Мультиспецифические антигенсвязывающие молекулы и их применения | |
EA201890222A1 (ru) | Полиспецифические антигенсвязывающие молекулы и их применения | |
BR112016013347A2 (pt) | anticorpo monoclonal humano neutralizante anti-il-33 | |
EA201400875A1 (ru) | Антитела к cd47 и способы их применения | |
CY1121964T1 (el) | Αντισωματα εναντιον toy csf-1r | |
EA201390933A1 (ru) | Антитела против мезотелина и иммуноконъюгаты | |
CR20150575A (es) | Anticuerpos humanos pac1 | |
WO2013059524A3 (en) | Antibodies directed against influenza | |
EA201390856A1 (ru) | Инактивация вирусов с применением улучшенного способа растворитель-детергент |